Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.72 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5559049 | 0.92 | PTGS2 (0.66) | PTGS2PTGS1HRH4TRPV1HDAC3 | |
| SCHEMBL5798156 | 0.91 | PTGS2 (0.64) | PTGS2PTGS1HRH4TRPV1HDAC3 | |
| SCHEMBL5558517 | 0.91 | PTGS2 (0.69) | PTGS2PTGS1HRH4TRPV1HDAC3 | |
| SCHEMBL5559036 | 0.90 | PTGS2 (0.63) | PTGS2PTGS1HRH4TRPV1CNR1 | |
| SCHEMBL5559109 | 0.89 | PTGS2 (0.89) | PTGS2PTGS1HRH4TRPV1HDAC3 | |
| SCHEMBL6467082 | 0.89 | PTGS2 (0.62) | PTGS2PTGS1TRPV1CNR1CNR2 | |
| SCHEMBL6424062 | 0.89 | PTGS2 (0.64) | PTGS2PTGS1HRH4TRPV1 | |
| SCHEMBL5798150 | 0.88 | PTGS2 (0.61) | PTGS2PTGS1TRPV1CNR1CNR2 | |
| SCHEMBL5558489 | 0.87 | PTGS2 (0.73) | PTGS2PTGS1HRH4TRPV1HDAC3 | |
| SCHEMBL5558825 | 0.86 | PTGS2 (0.55) | PTGS2PTGS1HRH4HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050032747-A1 | COX-2 and FAAH inhibitors | POLYMER CONCEPTS TECHNOLOGIES PBY, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032747-A1 | COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGS2 | PTGS2 3/4885PTGS1 6/4885HRH4 419/4885 |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | PTGS2 4/4885PTGS1 7/4885HRH4 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.